BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24651009)

  • 1. PI3Kδ inhibition hits a sensitive spot in B cell malignancies.
    Vanhaesebroeck B; Khwaja A
    Cancer Cell; 2014 Mar; 25(3):269-71. PubMed ID: 24651009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
    Fruman DA; Cantley LC
    N Engl J Med; 2014 Mar; 370(11):1061-2. PubMed ID: 24620870
    [No Abstract]   [Full Text] [Related]  

  • 3. Idelalisib: targeting PI3Kδ in B-cell malignancies.
    Gilbert JA
    Lancet Oncol; 2014 Mar; 15(3):e108. PubMed ID: 24809089
    [No Abstract]   [Full Text] [Related]  

  • 4. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
    Burger JA; Okkenhaug K
    Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
    Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
    N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
    Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
    Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.
    Okoli TC; Peer CJ; Dunleavy K; Figg WD
    Cancer Biol Ther; 2015; 16(2):204-6. PubMed ID: 25756507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell receptor inhibitors in chronic lymphocytic leukemia.
    Flinn IW
    Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
    [No Abstract]   [Full Text] [Related]  

  • 9. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia.
    Macias-Perez IM; Flinn IW
    Curr Hematol Malig Rep; 2013 Mar; 8(1):22-7. PubMed ID: 23114654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 13. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
    Keating GM
    Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.
    Herman SE; Johnson AJ
    Clin Cancer Res; 2012 Aug; 18(15):4013-8. PubMed ID: 22711705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
    Pongas G; Cheson BD
    Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
    Burger JA
    Curr Hematol Malig Rep; 2012 Mar; 7(1):26-33. PubMed ID: 22105489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
    Lopez JP; Jimeno A
    Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
    Alfaro J; Pérez de Arce F; Belmar S; Fuentealba G; Avila P; Ureta G; Flores C; Acuña C; Delgado L; Gaete D; Pujala B; Barde A; Nayak AK; Upendra TVR; Patel D; Chauhan S; Sharma VK; Kanno S; Almirez RG; Hung DT; Chakravarty S; Rai R; Bernales S; Quinn KP; Pham SM; McCullagh E
    J Pharmacol Exp Ther; 2017 May; 361(2):312-321. PubMed ID: 28298527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
    Greenwell IB; Flowers CR; Blum KA; Cohen JB
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.